NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

敗血症管理分析-第二部分:治療

Analysing Sepsis Management Part II: Treatments

出版商 Frost & Sullivan 商品編碼 979064
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
敗血症管理分析-第二部分:治療 Analysing Sepsis Management Part II: Treatments
出版日期: 2020年11月30日內容資訊: 英文 53 Pages
簡介

WHO(世界衛生組織)已指定敗血症為全球公共衛生重點。

在本報告中,我們調查和分析膿毒症,並提出理解和潛在機制,臨床前和臨床研究的重要性,膿毒症特異性生物標誌物在治療中的整合以及生物學信號/基因表達水平。它提供了有關要考慮的某些最重要方面的系統信息,例如檢測等。

目錄

第1章戰略要點

第2章執行摘要

第3章技術快照

  • 調查範圍:抗菌藥物的現狀和問題
  • 靶向治療藥物策略
  • 敗血症的發病機理
  • 敗血症涉及的一般細菌□與身體部位有關的死亡率

第4章現有的抗敗血病藥物

  • 敗血症治療/敗血性休克管理
  • 抗生素耐藥菌敗血症的治療
  • 敗血症的抗真菌藥物治療
  • 病毒性敗血症的治療

第5章未來的抗敗血症藥物

  • 敗血症/敗血性休克治療的進展
  • 嚴重敗血症的噬菌體療法
  • 膿毒症的細胞免疫療法
  • 基於抗體的膿毒症免疫療法
  • 膿毒症的蛋白質治療
  • 敗血症□治療
  • 敗血症疫苗
  • 用於治療敗血症的新型受體阻滯劑和益生菌
  • 用於治療敗血症的生物鹼和激動劑

第6章敗血症的臨床試驗

  • 用於控制敗血症的干預措施
  • 敗血症管理的臨床情況
  • 敗血症管理的3期臨床試驗
  • 膿毒症生物製劑的3期臨床試驗
  • 用於敗血症管理的3期臨床試驗藥物

第7章敗血症患者的狀況

  • 已發佈的敗血症專利數量穩步增長

第8章增長機會

  • 增長機會

第9章主要行業影響因素

  • 行業交流

下一步

目錄
Product Code: D9A0

Recent developments in Sepsis Treatment focused towards antibiotics, inhibitors, antibodies, peptides, recombinant proteins, antibacterial, antifungal, antivirals, vaccines, and probiotics

Sepsis is a life-threatening condition caused by overactivation of host immune system upon infections which may lead to organ failure and potentially death. World Health Organization designates sepsis as a global public health priority. Several studies conducted to understand the molecular basis of sepsis, septic shock, and organ failure. Despite extensive preclinical and clinical studies conducted over the past few decades, no significant improvement has observed in sepsis management. Lack of effective therapeutics raises the question about our understanding of sepsis pathophysiology. Another challenge comes with the heterogeneous nature of sepsis which depends on several factors, such as the pathogen causing infection and age, genetic make-up, existing medical condition, and lifestyle of the person. A further challenge comes with a measurement of the success of novel therapeutics.

This research study begins with highlighting the current status of sepsis treatment, such as antibiotics used with different kinds of pathogens along with antifungal and antiviral drugs used to treat infections; and also talks about the importance of fluid resuscitation and oxygen therapy in severe sepsis. A brief introduction to the course of sepsis development, the most important pathogen involved in sepsis and commonly affected body sites and associated mortality rates have discussed.

This study highlights some of the most important aspects considered to improve the current understanding and underlying mechanisms of sepsis, importance of preclinical and clinical studies, integration of sepsis specific biomarker in therapeutics, detecting biological signals and gene expression levels and designing novel interventions such as immunomodulatory and personalized approaches. Moreover, this study covers new sepsis treatment approaches such as phage therapy, cellular immunotherapy, antibody therapeutics, recombinant protein therapeutics, peptide therapeutics, microbial therapeutics, and vaccines as well as newly designed receptor blocker, receptor inhibitors, agonist, and alkaloids. A short introduction to clinical updates and patent landscape for sepsis therapeutics has provided. The study concludes with an emphasis on adopting new technologies to develop our understanding of sepsis that will help design breakthrough therapeutics.

Table of Contents

1.0 STRATEGIC IMPERATIVES

  • 1.1 THE STRATEGIC IMPERATIVE 8™
  • 1.2 THE STRATEGIC IMPERATIVE 8™
  • 1.3 THE IMPACT OF THE TOP THREE STRATEGIC IMPERATIVES ON SEPSIS THERAPEUTICS INDUSTRY
  • 1.4 ABOUT THE GROWTH PIPELINE ENGINE™
  • 1.5 GROWTH OPPORTUNITIES FUEL THE GROWTH PIPELINE ENGINE™

2.0 EXECUTIVE SUMMARY

  • 2.1 RESEARCH SCOPE: SEPSIS THERAPEUTICS
  • 2.2 ANALYSIS FRAMEWORK: FROST & SULLIVAN CORE VALUE
  • 2.3 Research Methodology: Five Steps Toward Success
  • 2.4 Key Findings of novel Sepsis therapeutics

3.0 TECHNOLOGY SNAPSHOT

  • 3.1 Research Scope: Current Status and Challenges of Sepsis Therapeutics
  • 3.2 Therapeutic strategies covered
  • 3.3 Pathogenesis of Sepsis
  • 3.4 Common bacteria and body sites involved in sepsis and associated mortality rates

4.0 EXISTING SEPSIS THERAPEUTICS

  • 4.1 Therapies for sepsis and septic shock management
  • 4.2 Sepsis Treatment for antibiotic resistant bacteria
  • 4.3 Antifungals treatment for sepsis
  • 4.4 Treatment of viral sepsis

5.0 UPCOMING SEPSIS THERAPEUTICS

  • 5.1 Advances in sepsis and septic shock therapeutics
  • 5.2 Phage Therapy for severe sepsis
  • 5.3 Cellular Immunotherapy for sepsis
  • 5.4 Antibody-based immunotherapy for sepsis
  • 5.5 Protein therapeutics for sepsis
  • 5.6 Peptide Therapeutics for sepsis
  • 5.7 Vaccines for sepsis
  • 5.8 Novel receptor blocker and probiotic for sepsis treatment
  • 5.9 Alkaloids and agonist for sepsis treatment

6.0 SEPSIS CLINICAL TRIALS

  • 6.1 Interventions Used for Sepsis Management
  • 6.2 Clinical Landscape for Sepsis Management
  • 6.3 Phase 3 Clinical Trials for Sepsis Management
  • 6.4 Phase 3 Clinical Trials for Biological therapeutics for Sepsis
  • 6.5 Drugs in Phase 3 Clinical Trials for Sepsis Management

7.0 SEPSIS PATENT LANDSCAPE

  • 7.1 Published patent count for sepsis is witnessing steady growth

8.0 GROWTH OPPORTUNITIES

  • 8.1 GROWTH OPPORTUNITY: NEW KNOWLEDGE AND TECHNOLOGIES ARE NEEDED TO BETTER UNDERSTAND SEPSIS, 2020
  • 8.2 GROWTH OPPORTUNITY: NEW KNOWLEDGE AND TECHNOLOGIES ARE NEEDED TO BETTER UNDERSTAND SEPSIS, 2020

9.0 KEY INDUSTRY INFLUENCERS

  • 9.1 Industry Interactions
  • 9.2 Industry Interactions

NEXT STEPS

  • YOUR NEXT STEPS
  • WHY FROST, WHY NOW?
  • LEGAL DISCLAIMER